STOCKHOLM, Tuesday, August 2010 [ME NewsWire]: * Provides superior blood pressure reductions of up to 50 mmHg in hypertensive patients with added-risk factors1 * Consistently greater blood pressure control/response rates than individual monotherapies 1 * Better tolerated than amlodipine monotherapy2 Embargoed until: 09.00hrs CEST, 31 August 2010 For NON-US and NON-UK Healthcare Media Only (BUSINESS [...]
September 1, 2010 | Posted in
Industry |
Read More »
For non-US Healthcare Media INGELHEIM, Germany, Tuesday, August 31st 2010 [ME NewsWire]: For medical media only (BUSINESS WIRE)– The European Society of Cardiology (ESC) today issued revised practice guidelines for the management of atrial fibrillation (AF), including guidance on the role of a novel oral treatment, dabigatran etexilate, for the prevention of stroke and systemic [...]
August 31, 2010 | Posted in
Industry |
Read More »
INGELHEIM, Germany, Sunday, August 2010 [ME NewsWire]: * Dabigatran etexilate 150mg BID was superior to warfarin in the reduction of stroke and systemic embolism irrespective of centre-based International Normalized Ratio (INR) control1 * Dabigatran etexilate 110mg BID reduced the rates of major bleeding compared to warfarin irrespective of centre-based INR control1 * Both dosages of [...]
August 30, 2010 | Posted in
Industry |
Read More »
1 Mission 1 Million – Getting to the Heart of Stroke Calls on Healthcare Professionals, Professional and Patient Organisations and the Public to Submit Ideas to Increase Awareness and Understanding of Atrial Fibrillation and Its Link to Debilitating Stroke STOCKHOLM, Sunday, August 29th 2010 [ME NewsWire]: (BUSINESS WIRE)– 1 Mission 1 Million – Getting to [...]
August 29, 2010 | Posted in
Industry |
Read More »
For NON-US Healthcare Media Only INGELHEIM, Germany, Monday, July 26th 2010 [ME NewsWire]: TWYNSTA®, the combination of telmisartan (the only angiotensin receptor blocker (ARB) with a broad cardiovascular protection indication) and amlodipine, provides effective and consistent blood pressure (BP) reduction throughout 24 hours Clinical trials have demonstrated that the single pill combination of telmisartan and [...]
July 26, 2010 | Posted in
Industry |
Read More »
New phase III data demonstrate clinically meaningful improvements in blood glucose control with linagliptin mono- and combination therapy INGELHEIM, Germany, Sunday, June 27th 2010 [ME NewsWire]: For non-US healthcare media only (BUSINESS WIRE)– Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association [...]
June 27, 2010 | Posted in
Industry |
Read More »
For NON-US and NON-UK Media Only INGELHEIM, Germany, Saturday, June 2010 [ME NewsWire]: (BUSINESS WIRE)– The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations [...]
June 21, 2010 | Posted in
Industry |
Read More »
INGELHEIM, Germany, Monday, June 2010 [ME NewsWire]: (BUSINESS WIRE)– For NON-US Medical Media Only Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient [...]
June 16, 2010 | Posted in
Healthcare |
Read More »
INGELHEIM, Germany, Friday, June 2010 [ME NewsWire]: Dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery1 Compared to enoxaparin, dabigatran etexilate significantly reduced the combined endpoint of major VTE and VTE-related death1 Dabigatran etexilate is associated with a similar bleeding risk [...]
June 15, 2010 | Posted in
Industry |
Read More »
